Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 8;4(2):101535.
doi: 10.1016/j.jacadv.2024.101535. eCollection 2025 Feb.

Genetic Predisposition to Coronary Artery Disease: Evaluating Statin Therapy in Elder Populations From PROSPER

Seung Hoan Choi  1   2 , Robin Young  3 , Satoshi Koyama  2   4 , J Wouter Jukema  5   6 , Stella Trompet  6   7 , Ian Ford  3 , Pradeep Natarajan  2   4   8 , Gina M Peloso  1
Affiliations

Genetic Predisposition to Coronary Artery Disease: Evaluating Statin Therapy in Elder Populations From PROSPER

Seung Hoan Choi et al. JACC Adv. .
No abstract available

Keywords: coronary artery disease; elderly population; polygenic score; statin therapy.

PubMed Disclaimer

Conflict of interest statement

Drs Peloso and Natarajan are supported by R01HL127564 from 10.13039/100000050National Heart, Lung, and Blood Institute (NHLBI). Dr Koyama is supported by K99HL169733 from 10.13039/100000050NHLBI. Dr Natarajan has received research grants from Allelica, 10.13039/100002429Amgen, 10.13039/100017567Apple, 10.13039/100008497Boston Scientific, 10.13039/100001127Genentech/10.13039/100004337Roche, and 10.13039/100004336Novartis; personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics, Foresite Labs, Genentech/Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, TenSixteen Bio, and Tourmaline Bio; equity in Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli, and TenSixteen Bio; and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

Figure 1
Figure 1
Evaluation of Coronary Artery Disease Risk Prediction and Statin Therapy by Polygenic Risk Score (A) Model prediction (area under the curve [AUC]) upon incorporating PRSCAD. (B) Forest plot showing the hazard ratio (HR) and 95% confidence intervals (CIs) for the PRS in the statin group versus nonstatin group. (C) Stratification of the CADPRS into categories: 0% to 25% (low), 25% to 75% (medium), and 75% to 100% (high), illustrating the effect of statin therapy within each stratum. CAD = coronary artery disease; PRSCAD = polygenic risk scores for CAD; ROC = receiver operation characteristic.
See this image and copyright information in PMC

References

    1. Bolli A., Di Domenico P., Pastorino R., Busby G.B., Botta G. Risk of coronary artery disease conferred by low-density lipoprotein cholesterol depends on polygenic background. Circulation. 2021;143:1452–1454. - PMC - PubMed
    1. Natarajan P., Young R., Stitziel N.O., et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation. 2017;135:2091–2101. - PMC - PubMed
    1. Bycroft C., Freeman C., Petkova D., et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203–209. - PMC - PubMed
    1. Ford I., Blauw G.J., Murphy M.B., et al. A prospective study of pravastatin in the elderly at risk (PROSPER): screening experience and baseline characteristics. Curr Contr Trials Cardiovasc Med. 2002;3:8. - PMC - PubMed
    1. Aragam K.G., Jiang T., Goel A., et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat Genet. 2022;54:1803–1815. - PMC - PubMed

LinkOut - more resources